日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Multimodality deep learning radiomics predicts pathological response after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma

多模态深度学习放射组学预测食管鳞状细胞癌新辅助放化疗后的病理反应

Liu, Yunsong; Wang, Yi; Hu, Xinyang; Wang, Xin; Xue, Liyan; Pang, Qingsong; Zhang, Huan; Ma, Zeliang; Deng, Heping; Yang, Zhaoyang; Sun, Xujie; Men, Yu; Ye, Feng; Men, Kuo; Qin, Jianjun; Bi, Nan; Zhang, Jing; Wang, Qifeng; Hui, Zhouguang

Integrating MR radiomics and dynamic hematological factors predicts pathological response to neoadjuvant chemoradiotherapy in esophageal cancer

整合磁共振放射组学和动态血液学因素可预测食管癌新辅助放化疗的病理反应

Liu, Yunsong; Ma, Zeliang; Bao, Yongxing; Wang, Xin; Men, Yu; Sun, Xujie; Ye, Feng; Men, Kuo; Qin, Jianjun; Bi, Nan; Xue, Liyan; Hui, Zhouguang

MR radiomics predicts pathological complete response of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a multicenter study

磁共振放射组学预测新辅助放化疗后食管鳞状细胞癌的病理完全缓解:一项多中心研究

Liu, Yunsong; Wang, Yi; Wang, Xin; Xue, Liyan; Zhang, Huan; Ma, Zeliang; Deng, Heping; Yang, Zhaoyang; Sun, Xujie; Men, Yu; Ye, Feng; Men, Kuo; Qin, Jianjun; Bi, Nan; Wang, Qifeng; Hui, Zhouguang

Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers

9MW2821(一种基于位点特异性单甲基 Auristatin E 的抗体-药物偶联物)的临床前评估,用于治疗表达 Nectin-4 的癌症

Wei Zhou, Peng Fang, Dongan Yu, Hongyuan Ren, Meng You, Long Yin, Fei Mei, Huikai Zhu, Zhenzhen Wang, Hui Xu, Yuxia Cao, Xiaowei Sun, Xiaohong Xu, Jianjun Bi, Jin Wang, Lanping Ma, Xin Wang, Lin Chen, Yongliang Zhang, Xiaowei Cen, Xi Zhu, Liguang Lou, Datao Liu, Xiaoding Tan, Jinliang Yang, Tao Meng

An elevated preoperative cholesterol-to-lymphocyte ratio predicts unfavourable outcomes in colorectal cancer liver metastasis patients receiving simultaneous resections: a retrospective study

术前胆固醇/淋巴细胞比值升高预示着接受同期切除术的结直肠癌肝转移患者预后不良:一项回顾性研究

Deng, Yiqiao; Chen, Qichen; Chen, Jinghua; Zhang, Yizhou; Zhao, Jianjun; Bi, Xinyu; Li, Zhiyu; Zhang, Yefan; Huang, Zhen; Cai, Jianqiang; Zhao, Hong

Nomogram for tumour response based on prospective cohorts of hepatocellular carcinoma patients receiving immunotherapy combined with targeted therapy: development and validation

基于接受免疫治疗联合靶向治疗的肝细胞癌患者前瞻性队列的肿瘤反应列线图:开发与验证

Chen, Qichen; Deng, Yiqiao; Zhao, Chuanhua; Huang, Zhen; Zhang, Wen; Yang, Yi; Bai, Yuxian; Tu, Jianfei; Li, Bo; Wu, Wei; Mao, Xianhai; Lv, Jing; Song, Tianqiang; Dai, Wenxiang; Zhao, Jianjun; Bi, Xinyu; Li, Zhiyu; Zhou, Jianguo; Zhang, Yefan; Chen, Xiao; Zhou, Aiping; Cai, Jianqiang; Xu, Jianming; Zhao, Hong

CDC42EP3 promotes colorectal cancer through regulating cell proliferation, cell apoptosis and cell migration

CDC42EP3通过调节细胞增殖、细胞凋亡和细胞迁移促进结直肠癌

Qiang Feng #, Dongkui Xu #, Mingyao Zhou, Zijian Wu, Zhiyuan Wu, Zheng Wang, Jianjun Bi, Wei Pei

What is the optimal number of neoadjuvant chemotherapy cycles for resectable colorectal liver oligometastases?

对于可切除的结直肠肝寡转移瘤,新辅助化疗的最佳周期数是多少?

Chen, Qichen; Li, Xingchen; Zhao, Jianjun; Bi, Xinyu; Li, Zhiyu; Huang, Zhen; Zhang, Yefan; Zhou, Jianguo; Zhao, Hong; Cai, Jianqiang

Upgraded nomograms for the prediction of complications and survival in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by hepatic resection

针对接受新辅助化疗后行肝切除术的结直肠癌肝转移患者,升级了用于预测并发症和生存率的列线图

Chen, Qichen; Mao, Rui; Zhao, Jianjun; Bi, Xinyu; Li, Zhiyu; Huang, Zhen; Zhang, Yefan; Zhou, Jianguo; Zhao, Hong; Cai, Jianqiang

From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?

从新辅助化疗完成到结直肠癌肝转移手术:最佳时机是什么?

Chen, Qichen; Mao, Rui; Zhao, Jianjun; Bi, Xinyu; Li, Zhiyu; Huang, Zhen; Zhang, Yefan; Zhou, Jianguo; Zhao, Hong; Cai, Jianqiang